Printer Friendly

CYTRX CORPORATION ANNOUNCES FILING OF IND APPLICATION FOR THERMAX(TM) GEL

 CYTRX CORPORATION ANNOUNCES FILING OF IND APPLICATION
 FOR THERMAX(TM) GEL
 NORCROSS, Ga., Jan. 14 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) announced today that it has filed an IND (Investigation New Drug) application with the U.S. Food and Drug Administration for its investigational agent TherMax(TM) Gel.
 When allowed, the IND will permit CytRx to begin human clinical trials to evaluate the safety and efficacy of ThertRx and may ultimately result in applications for burns and other wounds. It is an intriguing product since it can be applied to a burn or other wound as a cool soothing liquid which rapidly forms a protective gel. In addition to protecting the wound, experimental studies suggest TherMax(TM) promotes wound closure and reduces pain and scarring."
 CytRx Corporation is a biopharmaceutical company engaged in research and development of therapeutics incorporating copolymers. The company is developing human pharmaceutical products intended for use in the treatment of vascular, immune system and infectious diseases as well as burns. The company is also developing feed additives intended for growth enhancement in food animals, adjuvants for use in both human and veterinary vaccines, and is currently marketing Hunter's TiterMax(TM), an immunoadjuvant for use by the basic research community.
 -0- 1/14/92
 /CONTACT: CytRx Corporation, 404-368-9500/
 (CYTR) CO: CytRx Corporation ST: Georgia IN: MTC SU:


BN-BR -- AT002 -- 9406 01/14/92 09:11 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1992
Words:228
Previous Article:FRANK SINATRA, SHIRLEY MACLAINE, STEVE LAWRENCE, EYDIE GORME AT DESERT INN, LAS VEGAS, TO ANNOUNCE NEW ENTERTAINMENT POLICY
Next Article:IONICS FILES REGISTRATION STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION
Topics:


Related Articles
CYTRX CORPORATION ANNOUNCES NINE MONTHS EARNINGS
CYTRX CORPORATION ANNOUNCES NINE MONTHS EARNINGS
CYTRX CORPORATION ANNOUNCES NINE MONTHS EARNINGS
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF VICE PRESIDENT, MEDICAL & REGUALTORY AFFAIRS
CYTRX CORPORATION ANNOUNCES 1993 FIRST QUARTER RESULTS
FIRST OF TWO RHEOTHRX(R) STUDIES REPORTED: 9,000-PATIENT PHASE III STUDY IN ACUTE MYOCARDIAL INFARCTION PLANNED
CYTRX CORPORATION LICENSES OPHTHALMIC PATENT FROM BRUJO CORPORATION
CYTRX FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR MULTIPLE DRUG RESISTANT CANCER TREATMENT
CYTRX CORPORATION ANNOUNCES 1994 SIX MONTH RESULTS
CYTRX FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR PROTOX

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters